{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:29:38Z","timestamp":1772720978126,"version":"3.50.1"},"reference-count":25,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2018,1,30]]},"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Several studies indicate a prognostic value of sST2 and galectin-3 in heart failure (HF). While previous studies focused on ischaemic cause of HF, we investigated the role of sST2 and galectin-3 in patients with non-ischaemic dilated cardiomyopathy (DCM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>sST2 and galectin-3 serum concentrations were measured in 262 subjects with DCM. Survival rates were determined for all-cause mortality (ACM) and cardiac mortality (CM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In a univariate model, sST2 as a continuous variable was a predictor of ACM (HR 1.05;\u200995% CI 1.03 to 1.07,\u2009P&lt;0.001) and CM (HR 1.03;\u200995% CI 1.00 to 1.06, P=0.040). In the subgroup of patients with inflammatory and\/or viral DCM (DCMi\u22ceviral), the endpoints ACM (HR 1.10;\u200995% CI 1.05 to 1.17,\u2009P&lt;0.001) and CM (HR 1.10;\u200995% CI 1.02 to 1.18, P=0.013) were significant. In the subgroup of patients with idiopathic DCM, the endpoint ACM (HR 1.04;\u200995% CI 1.01 to 1.07, P=0.019) was significant. In a multivariate model, the prognostic value of the sST2 main group remained intact for ACM (HR 1.04; 95%\u2009CI 1.02 to 1.07, P=0.003).<\/jats:p>\n                  <jats:p>Univariate and multivariate analysis of galectin-3 as continuous variable did not show any significant result. However, in a quartile model, intermediate values of galectin-3 were significantly associated with a lower event rate of ACM and CM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The study revealed that sST2 predicts ACM and CM in patients with non-ischaemic HF and could be useful especially in patients with inflammatory background. Our findings that intermediate levels of galectin-3 allow for better prognosis were new and different to other investigations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"NCT03090425\" ext-link-type=\"clintrialgov\">NCT03090425<\/jats:ext-link>; Results.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/openhrt-2017-000750","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T20:20:35Z","timestamp":1519676435000},"page":"e000750","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure"],"prefix":"10.1136","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct03090425","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David","family":"Binas","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Cardiology, Philipps-University Marburg, Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Daniel","sequence":"additional","affiliation":[{"name":"Institute for Medical Biometry and Epidemiology, Philipps-University Marburg, Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"Richter","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiology, Philipps-University Marburg, Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Ruppert","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiology, Philipps-University Marburg, Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus-Dieter","family":"Schl\u00fcter","sequence":"additional","affiliation":[{"name":"Institute of Physiology, Justus-Liebig-University Giessen, Giessen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Schieffer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiology, Philipps-University Marburg, Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Pankuweit","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiology, Philipps-University Marburg, Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"key":"2025081709585454000_5.1.e000750.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfs105"},{"key":"2025081709585454000_5.1.e000750.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn309"},{"key":"2025081709585454000_5.1.e000750.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31829e8776"},{"key":"2025081709585454000_5.1.e000750.4","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.592"},{"key":"2025081709585454000_5.1.e000750.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2660"},{"key":"2025081709585454000_5.1.e000750.6","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000038705.69871.D9"},{"key":"2025081709585454000_5.1.e000750.7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1055\/s-0030-1250436","article-title":"Interleukin-33, a novel member of the IL-1\/IL-18 cytokine family, in cardiology and cardiac surgery","volume":"58","author":"Kunes","year":"2010","journal-title":"Thorac Cardiovasc Surg"},{"key":"2025081709585454000_5.1.e000750.8","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90498-7"},{"key":"2025081709585454000_5.1.e000750.9","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfp097"},{"key":"2025081709585454000_5.1.e000750.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfs006"},{"key":"2025081709585454000_5.1.e000750.11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.110.958223"},{"key":"2025081709585454000_5.1.e000750.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2013.12.004"},{"key":"2025081709585454000_5.1.e000750.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.087"},{"key":"2025081709585454000_5.1.e000750.14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cardfail.2015.07.017","article-title":"Prognostic value of serial measurements of soluble suppression of tumorigenicity 2 and galectin-3 in ambulatory patients with chronic heart failure","volume":"22","author":"Miller","year":"2016","journal-title":"J Card Fail"},{"key":"2025081709585454000_5.1.e000750.15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cardfail.2015.10.022","article-title":"Prognostic value of galectin-3 for adverse outcomes in chronic heart failure","volume":"22","author":"French","year":"2016","journal-title":"J Card Fail"},{"key":"2025081709585454000_5.1.e000750.16","first-page":"2648a","article-title":"European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"48","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"key":"2025081709585454000_5.1.e000750.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(03)00078-9"},{"key":"2025081709585454000_5.1.e000750.18","first-page":"3","article-title":"Myocarditis. A histopathologic definition and classification","volume":"1","author":"Aretz","year":"1987","journal-title":"Am J Cardiovasc Pathol"},{"key":"2025081709585454000_5.1.e000750.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00172-2"},{"key":"2025081709585454000_5.1.e000750.20","unstructured":"R&D Systems; Product Datasheet. Human ST2\/IL-33 R immunoassay quantikine ELISA kit. Catalog Number DST200."},{"key":"2025081709585454000_5.1.e000750.21","unstructured":"R&D Systems; Product Datasheet. Human galectin-3 immunoassay quantikine\u00ae ELISA kit. Catalog Number DGAL30."},{"key":"2025081709585454000_5.1.e000750.22","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijcard.2014.11.003","article-title":"Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure","volume":"179","author":"Broch","year":"2015","journal-title":"Int J Cardiol"},{"key":"2025081709585454000_5.1.e000750.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2015.03.033"},{"key":"2025081709585454000_5.1.e000750.24","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1997.6810"},{"key":"2025081709585454000_5.1.e000750.25","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s10554-016-0958-1","article-title":"Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients","volume":"32","author":"Hu","year":"2016","journal-title":"Int J Cardiovasc Imaging"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2017-000750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T16:59:05Z","timestamp":1755449945000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2017-000750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,2,26]]},"published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1136\/openhrt-2017-000750"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2017-000750","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}